Drugs / ALDASTOTUG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05718557 | May 2023 → May 2026 overdue | cancer | Pyxis Oncology, Inc | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALDASTOTUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068086 ↗ |
| Known as | PYX-106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05718557 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068086 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion” NCT05718557 ↗ |